Literature DB >> 27424367

Novel Approach to Outpatient Endometrial Biopsy to Detect Endometrial Cancer.

Maria C B de Leon, Howard H Wu, Ashley E Lennon, Giuseppe Del Priore.   

Abstract

OBJECTIVE: To evaluate a new device for obtaining endometrial biopsies which combines global endometrial disruption using a brush with a built-in suction process. STUDY
DESIGN: Endometrial biopsies were collected, using the GDP-Tao device, from fresh uteri hysterectomy specimens after completion of surgery. Results were compared to final hysterectomy pathology. Specificity and sensitivity and positive and negative predictive values were calculated.
RESULTS: Based on a sample size calculation, 42 patients were included in this study. Endometrial tissue adequate for diagnosis was obtained in 93% (39/42) of biopsies. Classifying atypia as a positive result, the sensitivity of the new device was 96% (23/24), with specificity of 87% (13/15). The positive predictive value was 92% (23/25) and the negative predictive value, 93% (13/14). There were 2 nondiagnostic (ND) samples from GDP-Tao with final pathology of benign endometrium. One specimen was ND on both GDP-Tao and final pathology due to absence of tissue after prior endometrial ablation. When stratified by uterine size, benign or malignant, the results were similar.
CONCLUSION: Our validation study showed encouraging results for the GDP-Tao, which combines tissue disruption and aspiration into a single process. The device provides a reliable means of obtaining adequate samples to accurately detect endometrial cancer with a high negative and positive predictive value.

Entities:  

Mesh:

Year:  2016        PMID: 27424367

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  1 in total

1.  The rising relative and absolute incidence of uterine cancer in specific populations.

Authors:  Ianeta Timoteo-Liaina; Kareem Khozaim; Yi-Ju A Chen; Lee Buenconsejo-Lum; Alan A Arslan; Roland Matthews; Giuseppe Del Priore
Journal:  Int J Gynaecol Obstet       Date:  2020-04-27       Impact factor: 3.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.